Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PROCROP

Financiado

Cerrado

Professional cross priming for ovary and prostate cancer

Immune responses are initiated by antigen presentation mediated by dendritic cells (DC). There is a minority subset of DC highly specialised in starting up cytotoxic T lymphocytes able to kill tumor cells. PROCROP aims to develop... ver más

28/02/2021

FUNOACION PARA LA...

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

FUNOACION PARA LA INVESTIG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 12M€

Fecha límite participación Sin fecha límite de participación.

Ver 8 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-02-28

PHC-13-2014: New therapies for chronic non-commu...

I+D

Cerrada hace 10 años

0% 76% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

8 Participantes

FUNOACION PARA LA INVESTIG

1.19M€ | Lider

LUIS CALVO SANZ

1.49M€ | Participante

MILTENYI BIOTEC GMBH

1.35M€ | Participante

CHUV

1.22M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EUIN2013-51221 PREPARACION DE PROPUESTA PARA HORIZONTE2020CUREMYELOMA 15K€ Cerrado

RIPECROP RNA-based cancer ImmunotheraPeutics to Enhance CROssPrimming 3M€ Cerrado

TrojanDC TrojanDC - A BREAKTHROUGH DEEP-TECH INNOVATION FOR CANCER IM... 75K€ Cerrado

DCanVAX A novel immuno-oncolytic virus-based dendritic cell therapeu... Cerrado

INCITE Immune Niches for Cancer ImmunoTherapy Enhancement 4M€ Cerrado

PanCaVax Personalised Pancreatic Cancer Vaccination Therapy derived f... 71K€ Cerrado

Duración del proyecto: 70 meses Fecha Inicio: 2015-04-07
Fecha Fin: 2021-02-28

Líder del proyecto

FUNOACION PARA LA INVESTIG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 12M€

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Immune responses are initiated by antigen presentation mediated by dendritic cells (DC). There is a minority subset of DC highly specialised in starting up cytotoxic T lymphocytes able to kill tumor cells. PROCROP aims to develop in three pilot clinical trials a suitable individualized cancer vaccine technology for castration resistant prostate cancer and metastatic cancer of the ovary that would complement currently available therapies to increase efficacy. The project applies recent compelling knowledge on the identity of the main antigen-presenting DC subsets for vaccine elicitation of cytotoxic T lymphocytes endowed with the ability to seek and destroy tumour cells (such immune mechanism is termed crosspriming). This unique opportunity for superior DCs for immunotherapy comes from the fact that Miltenyi, a successful European biotech company, has the necessary proprietary reagents (anti-BDCA-3 monoclonal antibody and immunomagnetic selection technology), as well as the expertise to clinically develop a strategy of DC isolation and short-term cell culture for immunotherapy. From the point of view of the tumor antigens, processed autologous tumor material will be mixed with defined common tumor antigens in the form of recombinant proteins. This novel combination will permit stronger and broader antitumor immune responses and more accurate monitoring of the ensuing immunity against the tumors. These features should make the novel DC vaccine more efficacious than the currently US-approved DC vaccine PROVENGE and other DCs preparations undergoing trials, such as those derived from monocytes. Three of the leading groups in immunotherapy of cancer in Europe would join forces to develop this individualized cell therapy technology in clinical trials for two highly prevalent and unsatisfactorily managed malignant conditions. Industrial partnership provides the unique advantage of producing a rigorously standardized product for eventual multicentre trials.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores